구조모아 (StructureMoa)항암 chemical structure spider web
방문Auto-discovered from ClinicalTrials.gov (98 linked trials). 선택한 코호트에서 보고된 효능: ORR 24% (ClinicalTrials.gov NCT03095274).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Muscle Invasive Bladder Cancer
Hepatocellular Carcinoma
Recruiting
2026-09-10
Data Confidence · High
Development Signal · Emerging
ADCs), have improved outcomes for patients with non-small cell
humanized for CTLA-4 and Fcγ receptors (FcγR), we show that ipilimumab and tremelimumab exhibit l
novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database
구조화 데이터
novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database
resistance to apoptosis, and metastasis
ADCs), have improved outcomes for patients with non-small cell
Muscle Invasive Bladder Cancer · biomarkers for dual immune checkpoint blockade remain insufficiently defined
targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
apoptosis, and metastasis
biomarkers for dual immune checkpoint blockade remain insufficiently defined
resistance to apoptosis, and metastasis
구조화 데이터
mouse tumor model
mouse
16.9
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Auto-discovered from ClinicalTrials.gov (98 linked trials). 선택한 코호트에서 보고된 효능: ORR 24% (ClinicalTrials.gov NCT03095274).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Muscle Invasive Bladder Cancer
Hepatocellular Carcinoma
Recruiting
2026-09-10
Data Confidence · High
Development Signal · Emerging
ADCs), have improved outcomes for patients with non-small cell
humanized for CTLA-4 and Fcγ receptors (FcγR), we show that ipilimumab and tremelimumab exhibit l
novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database
구조화 데이터
novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database
resistance to apoptosis, and metastasis
ADCs), have improved outcomes for patients with non-small cell
Muscle Invasive Bladder Cancer · biomarkers for dual immune checkpoint blockade remain insufficiently defined
targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
apoptosis, and metastasis
biomarkers for dual immune checkpoint blockade remain insufficiently defined
resistance to apoptosis, and metastasis
구조화 데이터
mouse tumor model
mouse
16.9
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.